Man Group
AKBA icon

Man Group’s Akebia Therapeutics AKBA Stock Holding History

Man Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177K Sell
155,396
-102,458
-40% -$122K ﹤0.01% 2277
2026
Q1 		$358K Buy
257,854
+49,259
+24% +$67.7K ﹤0.01% 2168
2025
Q4 		$336K Buy
208,595
+84,169
+68% +$176K ﹤0.01% 1993
2025
Q3 		$340K Buy
124,426
+82,715
+198% +$275K ﹤0.01% 1968
2025
Q2 		$152K Buy
+41,711
New +$115K ﹤0.01% 2102
2022
Q4 		– Sell
-43,873
Closed -$14K – 1994
2022
Q3 		$14K Buy
+43,873
New +$17.2K ﹤0.01% 1951
2022
Q2 		– Hold
0
– – – 2002
2021
Q2 		– Sell
-23,759
Closed -$80K – 1937
2021
Q1 		$80K Sell
23,759
-119,047
-83% -$429K ﹤0.01% 1807
2020
Q4 		$400K Sell
142,806
-4,732
-3% -$13.8K ﹤0.01% 1597
2020
Q3 		$370K Sell
147,538
-20,275
-12% -$178K ﹤0.01% 1590
2020
Q2 		$2.28M Sell
167,813
-51,293
-23% -$531K 0.01% 1011
2020
Q1 		$1.66M Sell
219,106
-121,069
-36% -$942K 0.01% 960
2019
Q4 		$2.15M Sell
340,175
-25,172
-7% -$120K 0.01% 1310
2019
Q3 		$1.43M Sell
365,347
-569,303
-61% -$2.44M 0.01% 1347
2019
Q2 		$4.52M Buy
934,650
+346,242
+59% +$1.97M 0.02% 989
2019
Q1 		$4.82M Buy
588,408
+190,604
+48% +$1.31M 0.02% 943
2018
Q4 		$2.2M Buy
397,804
+91,685
+30% +$717K 0.01% 1175
2018
Q3 		$2.7M Buy
306,119
+81,900
+37% +$733K 0.01% 1286
2018
Q2 		$2.24M Buy
224,219
+22,800
+11% +$228K 0.01% 1321
2018
Q1 		$1.92M Buy
+201,419
New +$2.82M 0.01% 1301

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Man Group's AKBA Position: Q2 2026 in Review

Man Group reduced its Akebia Therapeutics (AKBA) stake by 40% in Q2 2026, selling an estimated $122K and leaving 155,396 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Man Group first reported a position in AKBA in Q1 2018 and has held it in 19 quarters since. The position peaked at $4.82M in Q1 2019. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Man Group held 155,396 shares of Akebia Therapeutics worth $177K as of Q2 2026.
  • Man Group sold 102,458 Akebia Therapeutics shares in Q2 2026, an estimated $122K.
  • Akebia Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2277 holding.
  • Man Group first reported a position in Akebia Therapeutics in Q1 2018 and has held it in 19 quarters since.
  • Man Group's Akebia Therapeutics position peaked at $4.82M in Q1 2019.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.